Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
Journal of Clinical Medicine|September 13, 2025
Clinical Predictive Factors for the Development of Short Bowel Syndrome in a Cohort of Patients with Crohn's Disease: A Prospective StudyLaura Parisio, Angelo Del Gaudio, Jacopo Iaccarino, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 19, 2024
Suboptimal disease control and contributing factors in Italian IBD patients: The IBD-PODCAST StudyEmma Calabrese, Sara Onali, Angela Variola, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|November 23, 2021
Long-term, Real-life, Observational Study in Treating Outpatient Ulcerative Colitis with GolimumabAntonio Tursi, Giammarco Mocci, Walter Elisei, et al.
Biomedicines|April 23, 2022
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control StudyAlfredo Papa, Franco Scaldaferri, Marcello Covino, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 14, 2025
IBD impact on quality of life and perception of disease activity in Italian patients and physicians: An IBD-PODCAST study sub analysisEdoardo Vincenzo Savarino, Flavio Andrea Caprioli, Davide Giuseppe Ribaldone, et al.
European Journal of Internal Medicine|June 19, 2019
Vedolizumab is effective and safe in real-life treatment of inflammatory bowel diseases outpatients: A multicenter, observational study in primary inflammatory bowel disease centersAntonio Tursi, Giammarco Mocci, Roberto Faggiani, et al.
European Journal of Gastroenterology & Hepatology|March 20, 2021
Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatientsAntonio Tursi, Giammarco Mocci, Roberto Lorenzetti, et al.
United European Gastroenterology Journal|November 18, 2020
Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD studyDaniela Pugliese, Giuseppe Privitera, Francesca Rogai, et al.
The American Journal of Gastroenterology|April 25, 2022
An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha InhibitorsSara Onali, Daniela Pugliese, Flavio Andrea Caprioli, et al.
European Journal of Gastroenterology & Hepatology|October 1, 2019
Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease 'AGED' studyAnna Viola, Rita Monterubbianesi, Giuseppe Scalisi, et al.
Pageof 7